192 related articles for article (PubMed ID: 11298080)
1. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia.
Karunakaran S; Page RC; Wass JA
Clin Endocrinol (Oxf); 2001 Mar; 54(3):295-300. PubMed ID: 11298080
[TBL] [Abstract][Full Text] [Related]
2. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
3. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
Indirli R; Ferrante E; Sala E; Giavoli C; Mantovani G; Arosio M
Horm Cancer; 2019 Jun; 10(2-3):120-127. PubMed ID: 31001736
[TBL] [Abstract][Full Text] [Related]
5. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.
Pekić S; Medic Stojanoska M; Popovic V
Neuroendocrinology; 2019; 109(1):28-33. PubMed ID: 30347396
[TBL] [Abstract][Full Text] [Related]
6. The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia.
Pinto LP; Hanna FW; Evans LM; Davies JS; John R; Scanlon MF
Clin Endocrinol (Oxf); 2003 Nov; 59(5):580-4. PubMed ID: 14616880
[TBL] [Abstract][Full Text] [Related]
7. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
9. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?
Turner HE; Adams CB; Wass JA
Eur J Endocrinol; 1999 Jan; 140(1):43-7. PubMed ID: 10037250
[TBL] [Abstract][Full Text] [Related]
10. [Pregnancy in hyperprolactinemic patients].
Ventz M; Puhlmann B; Knappe G; Gerl H; Lehmann R; Rohde W
Zentralbl Gynakol; 1996; 118(11):610-5. PubMed ID: 9082694
[TBL] [Abstract][Full Text] [Related]
11. Hyperprolactinemia after menopause: Diagnosis and management.
Auriemma RS; Pirchio R; Pivonello R; Colao A
Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
[TBL] [Abstract][Full Text] [Related]
12. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
14. Is pregnancy the best treatment for hyperprolactinaemia?
Crosignani PG; Mattei AM; Scarduelli C; Cavioni V; Boracchi P
Hum Reprod; 1989 Nov; 4(8):910-2. PubMed ID: 2575622
[TBL] [Abstract][Full Text] [Related]
15. Serum prolactin bioactivity and immunoactivity in hyperprolactinaemic states.
Smith CR; Butler J; Hashim I; Norman MR
Ann Clin Biochem; 1990 Jan; 27 ( Pt 1)():3-8. PubMed ID: 2310154
[TBL] [Abstract][Full Text] [Related]
16. Prolactinomas and menopause: any changes in management?
Greenman Y
Pituitary; 2020 Feb; 23(1):58-64. PubMed ID: 31686376
[TBL] [Abstract][Full Text] [Related]
17. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
[TBL] [Abstract][Full Text] [Related]
18. Prolactin Secreting Pituitary Microadenoma: Results of Transsphenoidal Surgery After Medical Therapy With Dopamine Agonist.
Fraioli MF; Umana G; Pagano A; Fraioli B; Lunardi P
J Craniofac Surg; 2017 Jun; 28(4):992-994. PubMed ID: 28277481
[TBL] [Abstract][Full Text] [Related]
19. MRI--diagnostic and follow-up tool for microprolactinomas.
Seidl Z; Obenberger J; Marek J; Hána V; Vanĕcková M
Funct Neurol; 2000; 15(1):47-51. PubMed ID: 10842760
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]